Champions Oncology, INC 8-K filings

Champions Oncology announced record annual revenue of $59.4 million and positive Adjusted EBITDA for the fiscal year ended April 30, 2026, alongside a 12% increase in fourth-quarter revenue.

Champions Oncology appointed Brian Alexander, MD, MPH, to its board following Philip Breitfeld’s resignation, reinforcing a strategy to expand AI- and data-driven oncology R&D.

Champions Oncology announced its third quarter fiscal 2026 financial results, reporting record study service revenue of $16.6 million, up 32% year-over-year, despite a modest decline in total revenue.

Champions Oncology announced its second quarter fiscal 2026 financial results, reporting an 11% increase in total revenue to $15 million and record quarterly service revenue.

Champions Oncology, Inc. announced the results of its Annual Meeting of Stockholders, where all director nominees were re-elected, EisnerAmper LLP was ratified as the independent auditor, and executive compensation was approved.

Champions Oncology reported first-quarter fiscal 2026 revenue of $14.0 million and adjusted EBITDA of $60,000, alongside the appointment of Rob Brainin as CEO.

Champions Oncology announced record annual revenue of $57 million and a return to profitability for fiscal year 2025, driven by growth in research services and a new high-margin data licensing business.

Champions Oncology, Inc. announced the appointment of Robert Brainin as its new Chief Executive Officer, effective August 25, 2025, with current CEO Dr. Ronnie Morris transitioning to Executive Chairman.

Champions Oncology announces record quarterly revenue of $17.0 million and net income of $4.5 million for Q3 fiscal year 2025.

Champions Oncology announced a 17% increase in quarterly revenue to $13.5 million and an adjusted EBITDA of $1.1 million for the second quarter of fiscal year 2025.

Champions Oncology held its annual meeting on October 14, 2024, where stockholders elected directors, ratified the appointment of an accounting firm, and approved executive compensation on an advisory basis.

Champions Oncology reports the unexpected passing of its President, Mr. Brady Davis, who had served in the role since October 2023.

Champions Oncology announced a successful first quarter of fiscal year 2025, marked by a 12% revenue increase to $14.1 million and an adjusted EBITDA of $2.0 million.

Champions Oncology reported a 7% decrease in annual revenue but showed signs of recovery with a profitable fourth quarter.

Champions Oncology announced a 6% decrease in revenue for the third quarter of fiscal year 2024, alongside a decline in gross margin, as the company navigates a challenging economic environment in the biotech sector.